International Journal of Cancer, ISSN 0020-7136, 07/2019, Volume 145, Issue 2, pp. 318 - 326
Colorectal cancer (CRC) is one of the most common cancers in Latin America and the Caribbean, with the highest rates reported for Uruguay, Brazil and...
hereditary | colorectal cancer | lynch syndrome | Latin America | BREAST-CANCER | HEREDITARY CANCER | ONCOLOGY | MICROSATELLITE INSTABILITY | MUTATIONS | POLYMORPHISM | PREVALENCE | MLH1 | Genetic research | Research | Oncology, Experimental | Colorectal cancer | Cancer | MSH6 protein | MLH1 protein | Colorectal carcinoma | MSH2 protein | Genetic screening | Mini Review
hereditary | colorectal cancer | lynch syndrome | Latin America | BREAST-CANCER | HEREDITARY CANCER | ONCOLOGY | MICROSATELLITE INSTABILITY | MUTATIONS | POLYMORPHISM | PREVALENCE | MLH1 | Genetic research | Research | Oncology, Experimental | Colorectal cancer | Cancer | MSH6 protein | MLH1 protein | Colorectal carcinoma | MSH2 protein | Genetic screening | Mini Review
Journal Article
Pharmacogenomics Journal, ISSN 1470-269X, 12/2018, Volume 18, Issue 6, pp. 689 - 703
Methotrexate (MTX), a structural analog of folic acid, is widely employed in the treatment of different cancers and autoimmune diseases. Despite the successful...
GAMMA-GLUTAMYL-HYDROLASE | REDUCED FOLATE CARRIER | HIGH-DOSE METHOTREXATE | ACUTE LYMPHOBLASTIC-LEUKEMIA | GENETICS & HEREDITY | METHYLENETETRAHYDROFOLATE REDUCTASE GENE | MTHFR C677T POLYMORPHISM | TREATMENT RESPONSE | PHARMACOLOGY & PHARMACY | A1298C POLYMORPHISMS | RHEUMATOID-ARTHRITIS PATIENTS | SINGLE-NUCLEOTIDE POLYMORPHISMS | Predictive Value of Tests | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Immunosuppressive Agents - pharmacokinetics | Methotrexate - pharmacokinetics | Methylenetetrahydrofolate Reductase (NADPH2) - metabolism | Reduced Folate Carrier Protein - metabolism | Antimetabolites, Antineoplastic - administration & dosage | Patient Selection | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Clinical Decision-Making | Pharmacogenomic Variants | Immunosuppressive Agents - administration & dosage | Pharmacogenetics - methods | Risk Assessment | Reduced Folate Carrier Protein - genetics | Thymidylate Synthase - metabolism | Pharmacogenomic Testing | Thymidylate Synthase - genetics | Polymorphism, Genetic | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Immunosuppressive Agents - adverse effects | Methotrexate - administration & dosage | Precision Medicine - methods | Efflux | Parameters | Toxicity | Decision making | Medical treatment | Medical services | Data processing | Pharmacology | Methylenetetrahydrofolate reductase | Folic acid | Genetic markers | Methotrexate | Autoimmune diseases | Index Medicus
GAMMA-GLUTAMYL-HYDROLASE | REDUCED FOLATE CARRIER | HIGH-DOSE METHOTREXATE | ACUTE LYMPHOBLASTIC-LEUKEMIA | GENETICS & HEREDITY | METHYLENETETRAHYDROFOLATE REDUCTASE GENE | MTHFR C677T POLYMORPHISM | TREATMENT RESPONSE | PHARMACOLOGY & PHARMACY | A1298C POLYMORPHISMS | RHEUMATOID-ARTHRITIS PATIENTS | SINGLE-NUCLEOTIDE POLYMORPHISMS | Predictive Value of Tests | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Immunosuppressive Agents - pharmacokinetics | Methotrexate - pharmacokinetics | Methylenetetrahydrofolate Reductase (NADPH2) - metabolism | Reduced Folate Carrier Protein - metabolism | Antimetabolites, Antineoplastic - administration & dosage | Patient Selection | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Clinical Decision-Making | Pharmacogenomic Variants | Immunosuppressive Agents - administration & dosage | Pharmacogenetics - methods | Risk Assessment | Reduced Folate Carrier Protein - genetics | Thymidylate Synthase - metabolism | Pharmacogenomic Testing | Thymidylate Synthase - genetics | Polymorphism, Genetic | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Immunosuppressive Agents - adverse effects | Methotrexate - administration & dosage | Precision Medicine - methods | Efflux | Parameters | Toxicity | Decision making | Medical treatment | Medical services | Data processing | Pharmacology | Methylenetetrahydrofolate reductase | Folic acid | Genetic markers | Methotrexate | Autoimmune diseases | Index Medicus
Journal Article
Clinical Chemistry, ISSN 0009-9147, 11/2017, Volume 63, Issue 11, pp. 1734 - 1744
BACKGROUND: We sought to evaluate, in patients on a liver transplantation waiting list, potential biomarkers of the base calcineurin pathway activity with use...
SOLID-ORGAN TRANSPLANTATION | INFECTIONS | PHARMACOGENETICS | PHARMACODYNAMICS | IMMUNOSUPPRESSIVE DRUGS | MEDICAL LABORATORY TECHNOLOGY | RECIPIENTS | CELL | Leukocytes, Mononuclear - metabolism | Liver Transplantation | Pharmacogenetics | Calcineurin - genetics | Humans | Tacrolimus - pharmacology | Calcineurin - blood | Waiting Lists | Immunosuppressive Agents - pharmacology | Calcineurin - drug effects | Patient monitoring | Tacrolimus | Calcineurin | Blood cells | Liver | Physiological aspects | Transplantation | Methods | Drugs | Flow cytometry | Transplants & implants | Syngeneic grafts | CD8 antigen | Variability | Leukocytes (mononuclear) | Cardiovascular disease | Lymphocytes T | Cell activation | Allografts | Interleukin 2 | Lymphocytes | Peripheral blood mononuclear cells | CD25 antigen | Inhibition | Translocation | Interleukin 2 receptors | Pharmacodynamics | Liver diseases | Statistical analysis | Cytokines | Feasibility studies | T cell receptors | Pharmacology | Gene expression | Patients | Nuclear transport | Studies | Cytometry | NF-AT1 protein | Multivariate statistical analysis | Biomarkers | Nuclei (cytology) | Liver transplantation
SOLID-ORGAN TRANSPLANTATION | INFECTIONS | PHARMACOGENETICS | PHARMACODYNAMICS | IMMUNOSUPPRESSIVE DRUGS | MEDICAL LABORATORY TECHNOLOGY | RECIPIENTS | CELL | Leukocytes, Mononuclear - metabolism | Liver Transplantation | Pharmacogenetics | Calcineurin - genetics | Humans | Tacrolimus - pharmacology | Calcineurin - blood | Waiting Lists | Immunosuppressive Agents - pharmacology | Calcineurin - drug effects | Patient monitoring | Tacrolimus | Calcineurin | Blood cells | Liver | Physiological aspects | Transplantation | Methods | Drugs | Flow cytometry | Transplants & implants | Syngeneic grafts | CD8 antigen | Variability | Leukocytes (mononuclear) | Cardiovascular disease | Lymphocytes T | Cell activation | Allografts | Interleukin 2 | Lymphocytes | Peripheral blood mononuclear cells | CD25 antigen | Inhibition | Translocation | Interleukin 2 receptors | Pharmacodynamics | Liver diseases | Statistical analysis | Cytokines | Feasibility studies | T cell receptors | Pharmacology | Gene expression | Patients | Nuclear transport | Studies | Cytometry | NF-AT1 protein | Multivariate statistical analysis | Biomarkers | Nuclei (cytology) | Liver transplantation
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 17, pp. 1573 - 1582
In a randomized trial involving patients with acute stroke, the incidence of revascularization was higher with tenecteplase than with alteplase for intravenous...
ASSUMPTION-FREE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | BLINDED END-POINT | ACUTE MYOCARDIAL-INFARCTION | RANDOMIZED-TRIAL | THROMBOLYSIS | OPEN-LABEL | OUTCOMES | ENDOVASCULAR THROMBECTOMY | Cerebral Hemorrhage - chemically induced | Severity of Illness Index | Single-Blind Method | Time-to-Treatment | Humans | Middle Aged | Endovascular Procedures | Logistic Models | Male | Combined Modality Therapy | Stroke - drug therapy | Tissue Plasminogen Activator - therapeutic use | Tissue Plasminogen Activator - adverse effects | Fibrinolytic Agents - adverse effects | Stroke - surgery | Thrombectomy | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Female | Aged | Reperfusion - methods | Stroke - mortality | Tenecteplase | Stroke (Disease) | Treatment outcome | Care and treatment | Tissue plasminogen activator | Analysis | Dosage and administration | Research | Comparative analysis | Reperfusion injury | Cardiovascular system | Stroke | Territory | Intravenous administration | Medical imaging | Body weight | Thrombosis | Hemorrhage | Thrombolysis | Carotid arteries | Fibrin | Neurology | Brain research | Reperfusion | Ischemia | Consent | Cerebral blood flow | Drug dosages | Veins & arteries
ASSUMPTION-FREE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | BLINDED END-POINT | ACUTE MYOCARDIAL-INFARCTION | RANDOMIZED-TRIAL | THROMBOLYSIS | OPEN-LABEL | OUTCOMES | ENDOVASCULAR THROMBECTOMY | Cerebral Hemorrhage - chemically induced | Severity of Illness Index | Single-Blind Method | Time-to-Treatment | Humans | Middle Aged | Endovascular Procedures | Logistic Models | Male | Combined Modality Therapy | Stroke - drug therapy | Tissue Plasminogen Activator - therapeutic use | Tissue Plasminogen Activator - adverse effects | Fibrinolytic Agents - adverse effects | Stroke - surgery | Thrombectomy | Brain Ischemia - drug therapy | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Female | Aged | Reperfusion - methods | Stroke - mortality | Tenecteplase | Stroke (Disease) | Treatment outcome | Care and treatment | Tissue plasminogen activator | Analysis | Dosage and administration | Research | Comparative analysis | Reperfusion injury | Cardiovascular system | Stroke | Territory | Intravenous administration | Medical imaging | Body weight | Thrombosis | Hemorrhage | Thrombolysis | Carotid arteries | Fibrin | Neurology | Brain research | Reperfusion | Ischemia | Consent | Cerebral blood flow | Drug dosages | Veins & arteries
Journal Article
5.
Full Text
Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 11/2017, Volume 109, pp. 480 - 485
Individual variability is among the causes of toxicity and interruption of treatment in acute lymphoblastic leukemia (ALL) and severe non-Hodgkin lymphoma...
Non-Hodgkin lymphoma | Pharmacogenetics | Acute lymphoblastic leukemia | Methotrexate | Genetic polymorphisms | VARIANTS | HIGH-DOSE METHOTREXATE | MTHFR | TOXICITY | IMPACT | POLYMORPHISMS | DIHYDROFOLATE-REDUCTASE GENE | ACUTE LYMPHOBLASTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | ASSOCIATION | INSIGHTS | Humans | Middle Aged | Reduced Folate Carrier Protein - genetics | Genotype | Male | Lymphoma, Non-Hodgkin - genetics | Methotrexate - therapeutic use | Thymidylate Synthase - genetics | Polymorphism, Genetic | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Young Adult | Methotrexate - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antimetabolites, Antineoplastic - therapeutic use | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Adult | Female | Aged | Lymphoma, Non-Hodgkin - drug therapy | Solute Carrier Organic Anion Transporter Family Member 1b1 - genetics | Tetrahydrofolate Dehydrogenase - genetics | Leukemia | Analysis | Genes | Lymphomas | Glutamate | Index Medicus
Non-Hodgkin lymphoma | Pharmacogenetics | Acute lymphoblastic leukemia | Methotrexate | Genetic polymorphisms | VARIANTS | HIGH-DOSE METHOTREXATE | MTHFR | TOXICITY | IMPACT | POLYMORPHISMS | DIHYDROFOLATE-REDUCTASE GENE | ACUTE LYMPHOBLASTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | ASSOCIATION | INSIGHTS | Humans | Middle Aged | Reduced Folate Carrier Protein - genetics | Genotype | Male | Lymphoma, Non-Hodgkin - genetics | Methotrexate - therapeutic use | Thymidylate Synthase - genetics | Polymorphism, Genetic | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Young Adult | Methotrexate - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antimetabolites, Antineoplastic - therapeutic use | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Adolescent | Antimetabolites, Antineoplastic - adverse effects | Adult | Female | Aged | Lymphoma, Non-Hodgkin - drug therapy | Solute Carrier Organic Anion Transporter Family Member 1b1 - genetics | Tetrahydrofolate Dehydrogenase - genetics | Leukemia | Analysis | Genes | Lymphomas | Glutamate | Index Medicus
Journal Article
Clinical chemistry, ISSN 0009-9147, 10/2014, Volume 60, Issue 10, pp. 1336 - 1345
BACKGROUND: Although therapeutic drug monitoring has improved the clinical use of immunosuppressive drugs, there is still interpatient variability in efficacy...
RHEUMATOID-ARTHRITIS | CYCLOSPORINE-A | INHIBITION | THERAPY | IL2RA/CD25 GENE | ALLOGRAFT RECIPIENTS | PERIPHERAL-BLOOD | IMMUNOSUPPRESSIVE DRUGS | MEDICAL LABORATORY TECHNOLOGY | ASSOCIATION | T-CELLS | Tacrolimus - toxicity | Humans | Immunosuppressive Agents - pharmacokinetics | Male | Drug Monitoring - methods | CD4-Positive T-Lymphocytes - immunology | Calcineurin - genetics | Cell Nucleus - metabolism | Flow Cytometry | Tacrolimus - pharmacology | CD8-Positive T-Lymphocytes - metabolism | Adult | Female | Immunosuppressive Agents - pharmacology | Pharmacogenetics | NFATC Transcription Factors - metabolism | CD4-Positive T-Lymphocytes - metabolism | Cells, Cultured | Signal Transduction - genetics | Tacrolimus - pharmacokinetics | Immunosuppressive Agents - toxicity | Protein Transport | DNA - genetics | Interleukin-2 - genetics | CD8-Positive T-Lymphocytes - drug effects | Alleles | Polymorphism, Single Nucleotide | CD8-Positive T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - drug effects | Calcineurin - metabolism | Lymphocytes | Calcineurin | Drug interactions | Clinical trials | Observations | Health aspects | Methods | Proteins | Studies | Ethics | Signal transduction | Transplants & implants | Cytokines | Liver | Biomarkers | Clinical medicine | Phosphatase | Index Medicus
RHEUMATOID-ARTHRITIS | CYCLOSPORINE-A | INHIBITION | THERAPY | IL2RA/CD25 GENE | ALLOGRAFT RECIPIENTS | PERIPHERAL-BLOOD | IMMUNOSUPPRESSIVE DRUGS | MEDICAL LABORATORY TECHNOLOGY | ASSOCIATION | T-CELLS | Tacrolimus - toxicity | Humans | Immunosuppressive Agents - pharmacokinetics | Male | Drug Monitoring - methods | CD4-Positive T-Lymphocytes - immunology | Calcineurin - genetics | Cell Nucleus - metabolism | Flow Cytometry | Tacrolimus - pharmacology | CD8-Positive T-Lymphocytes - metabolism | Adult | Female | Immunosuppressive Agents - pharmacology | Pharmacogenetics | NFATC Transcription Factors - metabolism | CD4-Positive T-Lymphocytes - metabolism | Cells, Cultured | Signal Transduction - genetics | Tacrolimus - pharmacokinetics | Immunosuppressive Agents - toxicity | Protein Transport | DNA - genetics | Interleukin-2 - genetics | CD8-Positive T-Lymphocytes - drug effects | Alleles | Polymorphism, Single Nucleotide | CD8-Positive T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - drug effects | Calcineurin - metabolism | Lymphocytes | Calcineurin | Drug interactions | Clinical trials | Observations | Health aspects | Methods | Proteins | Studies | Ethics | Signal transduction | Transplants & implants | Cytokines | Liver | Biomarkers | Clinical medicine | Phosphatase | Index Medicus
Journal Article
Journal of Biomolecular Structure and Dynamics, ISSN 0739-1102, 12/2014, Volume 32, Issue 12, pp. 2033 - 2041
The CreA protein mediates carbon catabolite repression in the fungus Aspergillus nidulans. Its DNA-binding domain belongs to the Cys 2 -His 2 class, binding...
zinc finger | DNA-protein interaction | Aspergillus nidulans | TGEK linker | MOLECULAR-DYNAMICS | PROTEIN | LINKER SEQUENCES | RECOGNITION | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | 3 ZINC FINGERS | ZIF268-DNA COMPLEX | CARBON CATABOLITE REPRESSION | BIOPHYSICS | GENE-CLUSTER | BINDING-SITES | Fungal Proteins - chemistry | Repressor Proteins - chemistry | Zinc Fingers | Repressor Proteins - genetics | DNA, Fungal - chemistry | Fungal Proteins - genetics | Aspergillus nidulans - metabolism | Molecular Dynamics Simulation | Thermodynamics | Base Sequence | Computer Simulation | Mutation | Binding Sites
zinc finger | DNA-protein interaction | Aspergillus nidulans | TGEK linker | MOLECULAR-DYNAMICS | PROTEIN | LINKER SEQUENCES | RECOGNITION | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | 3 ZINC FINGERS | ZIF268-DNA COMPLEX | CARBON CATABOLITE REPRESSION | BIOPHYSICS | GENE-CLUSTER | BINDING-SITES | Fungal Proteins - chemistry | Repressor Proteins - chemistry | Zinc Fingers | Repressor Proteins - genetics | DNA, Fungal - chemistry | Fungal Proteins - genetics | Aspergillus nidulans - metabolism | Molecular Dynamics Simulation | Thermodynamics | Base Sequence | Computer Simulation | Mutation | Binding Sites
Journal Article
Clinical Chemistry, ISSN 0009-9147, 10/2017
BACKGROUND:We sought to evaluate, in patients on a liver transplantation waiting list, potential biomarkers of the base calcineurin pathway activity with use...
Life Sciences | Pharmaceutical sciences
Life Sciences | Pharmaceutical sciences
Journal Article
The Lancet Neurology, ISSN 1474-4422, 01/2018, Volume 17, Issue 1, pp. 47 - 53
General anaesthesia (GA) during endovascular thrombectomy has been associated with worse patient outcomes in observational studies compared with patients...
TRIAL | THERAPY | MR | CLINICAL NEUROLOGY | Outcome and Process Assessment (Health Care) - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Anesthesia, General - methods | Brain Ischemia - therapy | Humans | Middle Aged | Thrombectomy - methods | Aged, 80 and over | Female | Male | Aged | Stroke - therapy | Studies | Cardiovascular system | Stroke | Collaboration | Bias | Handbooks | Anesthesia | Systematic review | Blood pressure | Intubation | Patients | Meta-analysis
TRIAL | THERAPY | MR | CLINICAL NEUROLOGY | Outcome and Process Assessment (Health Care) - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Anesthesia, General - methods | Brain Ischemia - therapy | Humans | Middle Aged | Thrombectomy - methods | Aged, 80 and over | Female | Male | Aged | Stroke - therapy | Studies | Cardiovascular system | Stroke | Collaboration | Bias | Handbooks | Anesthesia | Systematic review | Blood pressure | Intubation | Patients | Meta-analysis
Journal Article